[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100552734":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":23,"centralContacts":33,"locations":42,"responsibleParty":110,"collaborators":112,"id":121,"slug":122,"hasResults":123,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":18,"eligibilityCriteria":127,"healthyVolunteers":123,"sex":128,"minAge":129,"maxAge":130,"enrollmentInfo":131,"targetDuration":18,"studyType":134,"phases":135,"briefSummary":137,"conditions":138,"keywords":140,"overallStatus":81,"whyStopped":18,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":153},{"fullName":5,"class":6},"Fox Chase Cancer Center","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Gene PilotLX","EXPERIMENTAL","Gene PilotLX is an eHealth decision support tool that is designed to empower Latinx cancer patients to decide their preferences for learning about secondary genetic information, communicate those preferences to their doctors, and provide the opportunity to discuss information with their families or others to feel they have made an informed decision. The tool will be available in both English and Spanish. It is web-based, has a voice-over, and is easy to navigate, with simple forward and backward buttons. Each section includes a different aspect of tumor genomic profiling, from basic information about what the test is and what the pros and cons are of the test, to culturally specific potential barriers or benefits to learning hereditary results. At the end, the tool provides tailored potential questions for a doctor that users can choose, which are summarized in a \"score card\" that can be printed or emailed.",[13],"Other: Gene PilotLX",{"label":15,"type":16,"description":17,"interventionNames":18},"TGP brochure","NO_INTERVENTION","Participants in the control arm will be provided a brochure about tumor genomic profiling (TGP) secondary hereditary risks, and what patients can decide about getting that information, including the pros and cons. It is literacy appropriate, incorporates visuals, and will also be offered in both English and Spanish.",null,[20],{"type":6,"name":9,"description":21,"armGroupLabels":22,"otherNames":18},"eHealth decision making tool regarding tumor genomic profiling",[9],[24,27,30],{"name":25,"affiliation":5,"role":26},"Michael J Hall, MD,MS","PRINCIPAL_INVESTIGATOR",{"name":28,"affiliation":29,"role":26},"Sarah B Bass, PhD, MPH","Temple University",{"name":31,"affiliation":32,"role":26},"Tracey A Revenson, PhD","Hunter College of City University of New York",[34,39],{"name":35,"role":36,"phone":37,"phoneExt":18,"email":38},"Michael J Hall, MD, MS","CONTACT","215-728-2861","michael.hall@fccc.edu",{"name":28,"role":36,"phone":40,"phoneExt":18,"email":41},"215-204-5110","sbass@temple.edu",[43,64,80,97],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"MD Anderson Cancer Center at Cooper","NOT_YET_RECRUITING","Camden","New Jersey","08103","United States","US",{"type":52,"coordinates":53},"Point",[54,55],-75.11962,39.92595,{"lat":55,"lon":54},[58,62],{"name":59,"role":36,"phone":60,"phoneExt":18,"email":61},"Andrea Nicholson, MPH","856-735-6249","nicholson-andrea@CooperHealth.edu",{"name":63,"role":26,"phone":18,"phoneExt":18,"email":18},"Rebecca J Jaslow, MD",{"facility":65,"status":45,"city":66,"state":66,"zip":67,"country":49,"countryCode":50,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"Herbert Irving Comprehensive Cancer Center","New York","10032",{"type":52,"coordinates":69},[70,71],-74.00597,40.71427,{"lat":71,"lon":70},[74,78],{"name":75,"role":36,"phone":76,"phoneExt":18,"email":77},"Erik Harden","212-305-6361","eh2828@cumc.columbia.edu",{"name":79,"role":26,"phone":18,"phoneExt":18,"email":18},"Yoanna S Pumpalova, MD",{"facility":5,"status":81,"city":82,"state":83,"zip":84,"country":49,"countryCode":50,"cosmosGeoPoint":85,"geoPoint":89,"contacts":90},"RECRUITING","Philadelphia","Pennsylvania","19111",{"type":52,"coordinates":86},[87,88],-75.16362,39.95238,{"lat":88,"lon":87},[91,92,96],{"name":25,"role":36,"phone":37,"phoneExt":18,"email":38},{"name":93,"role":36,"phone":94,"phoneExt":18,"email":95},"Yana Chertock, MA","215-214-3216","yana.chertock@fccc.edu",{"name":25,"role":26,"phone":18,"phoneExt":18,"email":18},{"facility":98,"status":81,"city":82,"state":83,"zip":99,"country":49,"countryCode":50,"cosmosGeoPoint":100,"geoPoint":102,"contacts":103},"Temple University Hospital","19122",{"type":52,"coordinates":101},[87,88],{"lat":88,"lon":87},[104,105,109],{"name":28,"role":36,"phone":40,"phoneExt":18,"email":41},{"name":106,"role":36,"phone":107,"phoneExt":18,"email":108},"Katie Singley","215- 204-1956","katie.singley@temple.edu",{"name":28,"role":26,"phone":18,"phoneExt":18,"email":18},{"type":111,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR",[113,114,115,116,119],{"name":29,"class":6},{"name":44,"class":6},{"name":65,"class":6},{"name":117,"class":118},"National Institutes of Health (NIH)","NIH",{"name":120,"class":118},"National Cancer Institute (NCI)","100552734","testing-gene-pilotlx-with-latinx-cancer-patients-100552734",false,"NCT06476938","Testing Gene PilotLX With Latinx Cancer Patients","Testing the Efficacy of an eHealth Decision Support Tool to Help Latinx Cancer Patients Make Informed Decisions About Tumor Genomic Testing","Inclusion Criteria:\n\nSelf-identified Latinx patients who:\n\n1. diagnosed with solid tumor cancers\n2. speak\u002Fread English or Spanish;\n3. can provide informed consent.\n\nExclusion Criteria:\n\nPatients with hematologic\u002Fliquid cancers (leukemia, lymphoma, multiple myeloma, etc.)","ALL","18 Years","80 Years",{"count":132,"type":133},232,"ESTIMATED","INTERVENTIONAL",[136],"NA","This is a randomized controlled trial designed to evaluate the efficacy of an electronic health decision support tool called Gene PilotLX to increase informed decision making regarding hereditary risk information from tumor genomic profiling (TGP) test among Latinx cancer patients recruited at four cancer centers.",[139],"Cancer",[141,142,143],"eHealth decision tool","Hispanic\u002FLatino","Tumor Genomic Profiling","2025-06-30",{"date":146,"type":147},"2025-07-03","ACTUAL",{"date":149,"type":147},"2025-05-30",{"date":151,"type":133},"2027-12-31",{"name":5,"class":6},4]